Literature DB >> 8293548

Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.

J A Styles1, A Davies, C K Lim, F De Matteis, L A Stanley, I N White, Z X Yuan, L L Smith.   

Abstract

The clastogenicity of tamoxifen and toremifene was tested in six human lymphoblastoid cell lines each expressing increased monooxygenase activity associated with a specific transfected human cytochrome P450 cDNA (CYP1A1, CYP1A2, CYP2D6, CYP2E1 or CYP3A4). The chemicals were also tested in a cell line (MCL-5) expressing elevated native CYP1A1 and containing transfected CYP1A2, CYP2A6, CYP2E1 and CYP3A4 and epoxide hydrolase, and in a cell line containing only the viral vector (Ho1). Dose-related increases in micronuclei were observed when cells expressing 2E1, 3A4, 2D6 or MCL-5 cells were exposed to tamoxifen. The positive responses in the cell lines were in the order MCL-5 > 2E1 > 3A4 > 2D6. Toremifene also gave positive results with 2E1, 3A4 and MCL-5 cells, although the responses were less marked and the positive effects required higher doses than with tamoxifen. A synthesized epoxide of tamoxifen was also tested in these cell lines and produced similar increases in the incidences of micronucleated cells. The increases in the responses observed with the epoxide were greater than with tamoxifen or toremifene. The P450 isoenzyme activities in these cells were in a range similar to those of human tumour-derived cell lines. Microsomes (1A1, 2A2, 2A6, 2B6, 2E1, 3A4 and 2D6) from these cells all metabolized tamoxifen. The major metabolite detected by HPLC was N-desmethyltamoxifen, and 4-hydroxytamoxifen was also detected in cells with cytochrome P450 2E1 and 2D6. These results are consistent with the following conclusions. (1) Tamoxifen requires metabolic activation to DNA-reactive species by specific CYP monooxygenases in order to exert its genotoxic effects. (2) The positive clastogenic effects elicited in lymphoblastoid cells by tamoxifen epoxide suggest that the genotoxic (and possibly the carcinogenic) effects of tamoxifen may be due to one or more epoxide metabolites that are generated intracellularly, probably in close proximity to the nucleus. (3) Tamoxifen is more genotoxic than toremifene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8293548     DOI: 10.1093/carcin/15.1.5

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Renzo Wolbold; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 3.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

5.  Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin.

Authors:  A M Otto; R Paddenberg; S Schubert; H G Mannherz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 6.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

7.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

8.  Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake.

Authors:  Jiang Yue; Jibran Khokhar; Sharon Miksys; Rachel F Tyndale
Journal:  Eur J Pharmacol       Date:  2009-03-13       Impact factor: 4.432

Review 9.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

10.  Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.

Authors:  F De Matteis; I N White; L L Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.